NOTTO COVID-19 vaccine guidelines for transplant recipients

3Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In December 2019 Novel corona virus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID 19 Vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID -19 infection or atleast diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno compromised patients should not receive live vaccines as they can cause vaccine related disease and hence the guidelines suggest that all transplant recipients should receive age appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population.

Cite

CITATION STYLE

APA

Kute, V., Agarwal, S. K., Prakash, J., Guleria, S., Shroff, S., Sharma, A., … Kumar, S. (2021). NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian Journal of Transplantation, 15(1), 1–3. https://doi.org/10.4103/ijot.ijot_2_21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free